Astellas Hits Sagent, Strides With Adenoscan IP Suit

Law360, Washington (June 21, 2011, 5:39 PM EDT) -- Astellas Pharma US LLC and affiliate Item Development AB hit Sagent Pharmaceuticals Inc. and Strides Arcolab Ltd. with a lawsuit in New Jersey federal court on Tuesday for allegedly violating a patent for the pharmacologic stress agent Adenoscan.

Sagent has filed an Abbreviated New Drug Application with the the U.S. Food and Drug Administration seeking approval to make a generic version of Adenoscan, according to Astellas.

The patent-in-suit is U.S. Patent No. 5,731,296, “a selective vasodilation by continuous adenosine infusion” that is set to expire in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.